The role of the JAK/STAT signal pathway in rheumatoid arthritis
Open accessThe DOI matches its Crossref record; 92 of the 92 references it cites were found in a registry or an index.
Abstract
Proinflammatory cytokine activation of the Janus kinase/signal transducers and activators of transcription (JAK/STAT) signal transduction pathway is a critical event in the pathogenesis and progression of rheumatoid arthritis. Under normal conditions, JAK/STAT signaling reflects the influence of negative regulators of JAK/STAT, exemplified by the suppressor of cytokine signaling and protein inhibitor of activated STAT. However, in rheumatoid arthritis (RA) both of these regulators are dysfunctional. Thus, continuous activation of JAK/STAT signaling in RA synovial joints results in the elevated level of matrix metalloproteinase gene expression, increased frequency of apoptotic chondrocytes and most prominently ‘apoptosis resistance’ in the inflamed synovial tissue. Tofacitinib, a JAK small molecule inhibitor, with selectivity for JAK2/JAK3 was approved by the United States Food and Drug Administration (US FDA) for the therapy of RA. Importantly, tofacitinib has demonstrated significant clinical efficacy for RA in the post-US FDA-approval surveillance period. Of note, the success of tofacitinib has spurred the development of JAK1, JAK2 and other JAK3-selective small molecule inhibitors, some of which have also entered the clinical setting, whereas other JAK inhibitors are currently being evaluated in RA clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Darnell, J. E. (1997) · Science · doi:10.1126/science.277.5332.1630 · Cited by 3,979
Tumor necrosis factor signaling
Wajant, H., Pfizenmaier, K., & Scheurich, P. (2003) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401189 · Cited by 2,359
Fibroblast‐like synoviocytes: key effector cells in rheumatoid arthritis
Bartok, B., & Firestein, G. S. (2010) · Immunological Reviews · doi:10.1111/j.0105-2896.2009.00859.x · Cited by 1,906
JAKS AND STATS: Biological Implications
Leonard, W. J., & O'Shea, J. J. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.293 · Cited by 1,804
Pathogenetic insights from the treatment of rheumatoid arthritis
McInnes, I. B., & Schett, G. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31472-1 · Cited by 1,345
JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
Schwartz, D. M., Kanno, Y., Villarino, A., Ward, M., Gadina, M., & O'Shea, J. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.201 · Cited by 1,266
Janus kinases in immune cell signaling
Ghoreschi, K., Laurence, A., & O’Shea, J. J. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00754.x · Cited by 1,149
Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis
Fleischmann, R., Kremer, J., Cush, J., Schulze-Koops, H., Connell, C. A., Bradley, J. D., Gruben, D., Wallenstein, G. V., Zwillich, S. H., & Kanik, K. S. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109071 · Cited by 1,024
Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
van Vollenhoven, R. F., Fleischmann, R., Cohen, S., Lee, E. B., García Meijide, J. A., Wagner, S., Forejtova, S., Zwillich, S. H., Gruben, D., Koncz, T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112072 · Cited by 945
SOCS Proteins: Negative Regulators of Cytokine Signaling
Krebs, D. L., & Hilton, D. J. (2001) · STEM CELLS · doi:10.1634/stemcells.19-5-378 · Cited by 827
Tofacitinib versus methotrexate in rheumatoid arthritis
Lee, E. B., Fleischmann, R., Hall, S., Wilkinson, B., Bradley, J. D., Gruben, D., Koncz, T., Krishnaswami, S., Wallenstein, G. V., Zang, C., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1310476 · Cited by 711
Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases
Schwartz, D. M., Bonelli, M., Gadina, M., & O'Shea, J. J. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2015.167 · Cited by 648
Baricitinib in Patients with Refractory Rheumatoid Arthritis
Genovese, M. C., Kremer, J., Zamani, O., Ludivico, C., Krogulec, M., Xie, L., Beattie, S. D., Koch, A. E., Cardillo, T. E., Rooney, T. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1507247 · Cited by 627
Synovial fibroblasts: key players in rheumatoid arthritis
Huber, L. C., Distler, O., Tarner, I., Gay, R. E., Gay, S., & Pap, T. (2006) · Rheumatology · doi:10.1093/rheumatology/kel065 · Cited by 607
The emerging safety profile of JAK inhibitors in rheumatic disease
Winthrop, K. L. (2017) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2017.23 · Cited by 590
Fridman, J. S., Scherle, P. A., Collins, R., Burn, T. C., Li, Y., Li, J., Covington, M. B., Thomas, B., Collier, P., Favata, M. F., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902819 · Cited by 463
Dougados, M., van der Heijde, D., Chen, Y.-C., Greenwald, M., Drescher, E., Liu, J., Beattie, S., Witt, S., de la Torre, I., Gaich, C., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210094 · Cited by 404
Shouda, T., Yoshida, T., Hanada, T., Wakioka, T., Oishi, M., Miyoshi, K., Komiya, S., Kosai, K.-I., Hanakawa, Y., Hashimoto, K., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13568 · Cited by 395
Hodge, J. A., Kawabata, T. T., Krishnaswami, S., Clark, J. D., Telliez, J., Dowty, M. E., Menon, S. S., Lamba, M., & Zwillich, S. H. (2016) · PubMed · Cited by 374
Baker, K. F., & Isaacs, J. D. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-211555 · Cited by 370
Wollenhaupt, J., Silverfield, J., Lee, E. B., Curtis, J. R., Wood, S. P., Soma, K., Nduaka, C. I., Benda, B., Gruben, D., Nakamura, H., et al. (2014) · The Journal of Rheumatology · doi:10.3899/jrheum.130683 · Cited by 301
The Jak-Stat Pathway: Cytokine Signalling from the Receptor to the Nucleus
Heim, M. H. (1999) · Journal of Receptors and Signal Transduction · doi:10.3109/10799899909036638 · Cited by 271
Cardiovascular disease in autoimmune rheumatic diseases
Hollan, I., Meroni, P. L., Ahearn, J. M., Cohen Tervaert, J. W., Curran, S., Goodyear, C. S., Hestad, K. A., Kahaleh, B., Riggio, M., Shields, K., et al. (2013) · Autoimmunity Reviews · doi:10.1016/j.autrev.2013.03.013 · Cited by 270
The good and the bad faces of STAT1 in solid tumours
Meissl, K., Macho-Maschler, S., Müller, M., & Strobl, B. (2017) · Cytokine · doi:10.1016/j.cyto.2015.11.011 · Cited by 264
Negative regulation of cytokine signaling
Greenhalgh, C. J., & Hilton, D. J. (2001) · Journal of Leukocyte Biology · doi:10.1189/jlb.70.3.348 · Cited by 258
Immunologic Mechanisms in the Pathogenesis of Rheumatoid Arthritis
Firestein, G. S. (2005) · JCR: Journal of Clinical Rheumatology · doi:10.1097/01.rhu.0000166673.34461.33 · Cited by 243
Westhovens, R., Taylor, P. C., Alten, R., Pavlova, D., Enríquez-Sosa, F., Mazur, M., Greenwald, M., Van der Aa, A., Vanhoutte, F., Tasset, C., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210104 · Cited by 236
Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease
Kontzias, A., Kotlyar, A., Laurence, A., Changelian, P., & O'Shea, J. J. (2012) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2012.06.008 · Cited by 233
Van Rompaey, L., Galien, R., van der Aar, E. M., Clement-Lacroix, P., Nelles, L., Smets, B., Lepescheux, L., Christophe, T., Conrath, K., Vandeghinste, N., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1201348 · Cited by 231
Kavanaugh, A., Kremer, J., Ponce, L., Cseuz, R., Reshetko, O. V., Stanislavchuk, M., Greenwald, M., Van der Aa, A., Vanhoutte, F., Tasset, C., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210105 · Cited by 229
Shi, J. G., Chen, X., Lee, F., Emm, T., Scherle, P. A., Lo, Y., Punwani, N., Williams, W. V., & Yeleswaram, S. (2014) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.354 · Cited by 222
The Immunopathogenesis of Rheumatoid Arthritis
Imboden, J. B. (2009) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.4.110807.092254 · Cited by 212
NF‐κB regulation: the nuclear response
Mankan, A. K., Lawless, M. W., Gray, S. G., Kelleher, D., & McManus, R. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00632.x · Cited by 189
The role of T cells in rheumatoid arthritis: new subsets and new targets
Toh, M.-L., & Miossec, P. (2007) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e32805e87e0 · Cited by 183
Shi, J. G., Chen, X., McGee, R. F., Landman, R. R., Emm, T., Lo, Y., Scherle, P. A., Punwani, N. G., Williams, W. V., & Yeleswaram, S. (2011) · The Journal of Clinical Pharmacology · doi:10.1177/0091270010389469 · Cited by 168
Molecular and cellular basis of rheumatoid joint destruction
Karouzakis, E., Neidhart, M., Gay, R. E., & Gay, S. (2006) · Immunology Letters · doi:10.1016/j.imlet.2006.04.011 · Cited by 167
Molecular Pathways: Molecular Basis for Sensitivity and Resistance to JAK Kinase Inhibitors
Meyer, S. C., & Levine, R. L. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0279 · Cited by 159
Selective JAK inhibitors in development for rheumatoid arthritis
Norman, P. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.918604 · Cited by 157
Checkpoint inhibitors in hematological malignancies
Ok, C. Y., & Young, K. H. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0474-3 · Cited by 152
Doi, T., Ishikawa, T., Okayama, T., Oka, K., Mizushima, K., Yasuda, T., Sakamoto, N., Katada, K., Kamada, K., Uchiyama, K., et al. (2017) · Oncology Reports · doi:10.3892/or.2017.5399 · Cited by 150
Signal transduction in rheumatoid arthritis
Sweeney, S. E., & Firestein, G. S. (2004) · Current Opinion in Rheumatology · doi:10.1097/00002281-200405000-00011 · Cited by 144
Janus kinase inhibitors for rheumatoid arthritis
Yamaoka, K. (2016) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2016.03.006 · Cited by 142
Jiang, J., Ghoreschi, K., Deflorian, F., Chen, Z. J., Perreira, M., Pesu, M., Smith, J. A., Nguyễn, Ð.-T., Liu, E. H., Leister, W., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm801142b · Cited by 131
Genovese, M. C., van Vollenhoven, R. F., Pacheco‐Tena, C., Zhang, Y., & Kinnman, N. (2016) · Arthritis & Rheumatology · doi:10.1002/art.39473 · Cited by 128
Negative Regulators of JAK/STAT Signaling in Rheumatoid Arthritis and Osteoarthritis
Malemud, C. J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18030484 · Cited by 125
Self-citationKivitz, A., Gutiérrez-Ureña, S. R., Poiley, J. E., et al. (2016) · Arthritis & Rheumatology · doi:10.1002/art.39955 · Cited by 110
Mesa, R. A. (2010) · PubMed · Cited by 105
IL-15 activates the Jak3/STAT3 signaling pathway to mediate glucose uptake in skeletal muscle cells
Krolopp, J. E., Thornton, S. M., & Abbott, M. J. (2016) · Frontiers in Physiology · doi:10.3389/fphys.2016.00626 · Cited by 104
Targeting JAK/STAT Signaling Pathway in Inflammatory Diseases
Malemud, C. J., & Pearlman, E. M. (2009) · Current Signal Transduction Therapy · doi:10.2174/157436209789057467 · Cited by 103
Self-citationThe Therapeutic Potential for PI3K Inhibitors in Autoimmune Rheumatic Diseases
Banham-Hall, E., Clatworthy, M. R., & Okkenhaug, K. (2012) · The Open Rheumatology Journal · doi:10.2174/1874312901206010245 · Cited by 101
B cells in rheumatoid arthritis
Bugatti, S., Codullo, V., Caporali, R. F., & Montecucco, C. (2007) · Autoimmunity Reviews · doi:10.1016/j.autrev.2007.02.008 · Cited by 99
SOCS3 revisited: a broad regulator of disease, now ready for therapeutic use?
Mahony, R., Ahmed, S., Diskin, C., & Stevenson, N. J. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2234-x · Cited by 98
Ito, M., Yamazaki, S., Yamagami, K., Kuno, M., Morita, Y., Okuma, K., Nakamura, K., Chida, N., Inami, M., Inoue, T., et al. (2016) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2016.12.001 · Cited by 96
Immunological Consequences of JAK Inhibition: Friend or Foe?
McLornan, D. P., Khan, A. A., & Harrison, C. N. (2015) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-015-0284-z · Cited by 94
Update on cytokines in rheumatoid arthritis
Brennan, F. M., & Beech, J. T. (2007) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e32805e87f1 · Cited by 94
Genovese, M. C., Greenwald, M., Codding, C. E., et al. (2017) · Arthritis & Rheumatology · doi:10.1002/art.40054 · Cited by 92
An update on the cytokine network in rheumatoid arthritis
Miossec, P. (2004) · Current Opinion in Rheumatology · doi:10.1097/00002281-200405000-00009 · Cited by 91
Cell-cell Interactions in Rheumatoid Arthritis Synovium
Fox, D. A., Gizinski, A. M., Morgan, R. L., & Lundy, S. K. (2010) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2010.02.004 · Cited by 90
Giordanetto, F., & Kroemer, R. T. (2002) · Protein Engineering Design and Selection · doi:10.1093/protein/15.9.727 · Cited by 89
Emerging cytokine targets in rheumatoid arthritis
Asquith, D. L., & McInnes, I. B. (2007) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e3280eec78c · Cited by 88
Klünder, B., Mohamed, M.-E. F., & Othman, A. A. (2018) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0605-6 · Cited by 83
Recent Progress in JAK Inhibitors for the Treatment of Rheumatoid Arthritis
Nakayamada, S., Kubo, S., Iwata, S., & Tanaka, Y. (2016) · BioDrugs · doi:10.1007/s40259-016-0190-5 · Cited by 83
Vanhoutte, F. P., Mazur, M., Voloshyn, O. I., Stanislavchuk, M., der Aa, A. V., Namour, F., Galien, R., Meuleners, L., & Klooster, G. A. E. V. '. (2017) · Arthritis & Rheumatology · doi:10.1002/art.40186 · Cited by 83
Constitutive Activation of STATs Upon In Vivo Human Immunodeficiency Virus Infection
Bovolenta, C., Camorali, L., Lorini, A. L., Ghezzi, S., Vicenzi, E., Lazzarin, A., & Poli, G. (1999) · Blood · doi:10.1182/blood.v94.12.4202 · Cited by 82
A Role for Soluble IL-6 Receptor in Osteoarthritis
Akeson, G., & Malemud, C. J. (2017) · Journal of Functional Morphology and Kinesiology · doi:10.3390/jfmk2030027 · Cited by 80
Self-citationVyas, D., O’Dell, K. M., Bandy, J. L., & Boyce, E. G. (2013) · Annals of Pharmacotherapy · doi:10.1177/1060028013512790 · Cited by 79
IL‐15 regulates Bcl‐2 family members Bim and Mcl‐1 through JAK/STAT and PI3K/AKT pathways in T cells
Shenoy, A. R., Kirschnek, S., & Häcker, G. A. (2014) · European Journal of Immunology · doi:10.1002/eji.201344238 · Cited by 74
Haan, S., Margue, C., Engrand, A., Rolvering, C., de Leur, H. S.-V., Heinrich, P. C., Behrmann, I., & Haan, C. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.2.998 · Cited by 71
Lao, M., Shi, M., Zou, Y., Huang, M., Ye, Y., Qiu, Q., Xiao, Y., Zeng, S., Liang, L., Yang, X., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1403254 · Cited by 66
Mahajan, S., Hogan, J. K., Shlyakhter, D., Oh, L., Salituro, F. G., Farmer, L. J., & Hoock, T. C. (2015) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.221176 · Cited by 65
Tofacitinib for the treatment of rheumatoid arthritis
Zerbini, C. A. F., & Lomonte, A. B. V. (2012) · Expert Review of Clinical Immunology · doi:10.1586/eci.12.19 · Cited by 63
STAT3 Inhibitors: Finding a Home in Lymphoma and Leukemia
Munoz, J. L., Dhillon, N., Jankú, F., Watowich, S. S., & Hong, D. S. (2014) · The Oncologist · doi:10.1634/theoncologist.2013-0407 · Cited by 62
ERK Inhibitors as a Potential New Therapy for Rheumatoid Arthritis
Ohori, M. (2008) · Drug News & Perspectives · doi:10.1358/dnp.2008.21.5.1219006 · Cited by 59
Genovese, M. C., Yang, F., Østergaard, M., & Kinnman, N. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-208901 · Cited by 52
Filgotinib for the treatment of rheumatoid arthritis
Taylor, P. C., Azeez, M., & Kiriakidis, S. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1372422 · Cited by 41
Editorial: Decernotinib: A Next‐Generation Jakinib
Gadina, M., Schwartz, D. M., & O'Shea, J. J. (2016) · Arthritis & Rheumatology · doi:10.1002/art.39463 · Cited by 40
Efficacy of baricitinib in the treatment of rheumatoid arthritis
Richez, C., Truchetet, M., Kostine, M., Schaeverbeke, T., & Bannwarth, B. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1359256 · Cited by 40
Small molecular compounds in development for rheumatoid arthritis
van Vollenhoven, R. (2013) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e32835fd828 · Cited by 38
IL-2 activation of STAT5 enhances production of IL-10 from human cytotoxic regulatory T cells, HOZOT
Tsuji‐Takayama, K., Suzuki, M., Yamamoto, M., Harashima, A., Okochi, A., Otani, T., Inoue, T., Sugimoto, A., Motoda, R., Yamasaki, F., et al. (2007) · Experimental Hematology · doi:10.1016/j.exphem.2007.09.010 · Cited by 38
Targeting the JAK-STAT pathway in lymphoma: a focus on pacritinib
Derenzini, E., & Younes, A. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.775244 · Cited by 38
Janus Kinases: An Ideal Target for the Treatment of Autoimmune Diseases
Gadina, M. (2013) · Journal of Investigative Dermatology Symposium Proceedings · doi:10.1038/jidsymp.2013.29 · Cited by 33
Elwood, F., Witter, D. J., Piesvaux, J., Kraybill, B. C., Bays, N. W., Alpert, C., Goldenblatt, P., Qu, Y., Ivanovska, I. L., Lee, H., et al. (2017) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.239723 · Cited by 33
Targeting Cytokines, Chemokines and Adhesion Molecules in Rheumatoid Arthritis
Malemud, C. J., & Reddy, S. (2008) · Current Rheumatology Reviews · doi:10.2174/157339708786263933 · Cited by 32
Self-citationThe Role of Apoptosis in Arthritis
Malemud, C. J., & Gillespie, H. (2005) · Current Rheumatology Reviews · doi:10.2174/1573397054023146 · Cited by 32
Self-citationMalignancy and Janus Kinase Inhibition
Sivaraman, P., & Cohen, S. B. (2016) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2016.09.008 · Cited by 32
Recent advances in neutralizing the IL-6 pathway in arthritis
Malemud, C. J. (2009) · Open Access Rheumatology Research and Reviews · doi:10.2147/oarrr.s6266 · Cited by 29
Self-citationProgress Toward JAK1-Selective Inhibitors
Menet, C. J., Mammoliti, O., & López‐Ramos, M. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.14.149 · Cited by 29
Fleischmann, R. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1370453 · Cited by 20
Advances in kinase inhibition: treating rheumatic diseases and beyond
Gadina, M. (2014) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000023 · Cited by 19
Qiu, M., Mo, L., Li, J., Liang, H., Zhu, W., Zheng, X., Duan, X., & Xu, W. (2019) · Clinical Rheumatology · doi:10.1007/s10067-019-04894-7 · Cited by 17
Regulation of Chondrocyte Matrix Metalloproteinase Gene Expression
Malemud, C. J. (2013) · Springer eBooks · doi:10.1007/978-1-4614-9233-7_5 · Cited by 11
Self-citationZhu, T., Parker, B., Wojtkowski, T., Nishimura, T., Garg, J. P., Han, D., Fisniku, O., & Keirns, J. J. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0474-4 · Cited by 10
Cited by
The role of JAK/STAT signaling pathway and its inhibitors in diseases.
Xin, P., Xu, X., Deng, C., Liu, S., Wang, Y., Zhou, X., Ma, H., Wei, D., & Sun, S. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106210 · Cited by 1,010
Methotrexate and its mechanisms of action in inflammatory arthritis
Cronstein, B. N., & Aune, T. M. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-0373-9 · Cited by 677
Signaling pathways in rheumatoid arthritis: implications for targeted therapy
Ding, Q., Hu, W., Wang, R., Yang, Q., Zhu, M., Li, M., Cai, J., Rose, P., Mao, J., & Zhu, Y. Z. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01331-9 · Cited by 478
Ulgen, E., Ozisik, O., & Sezerman, O. U. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00858 · Cited by 469
Promising Therapeutic Targets for Treatment of Rheumatoid Arthritis
Huang, J., Fu, X., Chen, X., Li, Z., Huang, Y., & Liang, C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.686155 · Cited by 340
Metadata
- Authors
- Malemud, C. J.
- Venue
- Therapeutic Advances in Musculoskeletal Disease
- Publisher
- SAGE Publications
- Published
- 2018-05-19
- Volume
- 10
- Issue
- 5-6
- Pages
- 117-127
- ISSN
- 1759-720X (ISSN-L)
- 1759-7218
- OpenAlex
- W2803975545
- Cited by
- 302
- References
- 92
- FWCI
- 20.91
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.